Hansa Biopharma AB

Hansa Biopharma Appoints Renée Aguiar-Lucander as New CEO, Marking New Growth Phase

a month ago

• Renée Aguiar-Lucander has been appointed as the new CEO of Hansa Biopharma AB, effective immediately, replacing Søren Tulstrup who steps down after seven years with the company. • Aguiar-Lucander brings significant experience from her seven-year tenure as CEO of Calliditas Therapeutics, where she led a successful dual NASDAQ listing and launched the first approved drug for IgA nephropathy in the U.S. • The leadership change signals Hansa Biopharma's transition into a new growth phase, with the Board expressing confidence in Aguiar-Lucander's ability to advance the company's strategic positioning.

Hansa Biopharma's Imlifidase Shows Promise in Guillain-Barré Syndrome and Anti-GBM Disease

4 months ago

• Hansa Biopharma announced positive Phase 2 results for imlifidase in Guillain-Barré Syndrome (GBS), showing rapid functional improvement in patients. • The company completed enrollment in the pivotal Phase 3 GOOD-IDES-02 trial of imlifidase for anti-glomerular basement membrane (anti-GBM) disease. • A Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome has been initiated in collaboration with Genethon. • Hansa Biopharma anticipates submitting a Biologics License Application (BLA) to the FDA for imlifidase in kidney transplantation in late 2025.

Hansa Biopharma's HNSA-5487 Shows Rapid IgG Reduction and Redosing Potential in Phase 1 Trial

8 months ago

• HNSA-5487 demonstrated a rapid and substantial reduction of IgG levels, exceeding 95% within hours post-treatment, in a Phase 1 trial. • IgG levels returned to the normal range six months after the initial dose, confirming the drug's efficacy and mirroring results of imlifidase. • The trial indicated a favorable safety and tolerability profile for HNSA-5487, with no serious adverse events reported among participants. • HNSA-5487 exhibited lower anti-drug antibody levels and reduced ADA responses compared to imlifidase, suggesting a clear redosing potential.